{"product_id":"fremanezumab-for-chronic-migraine-a-new-preventive-treatment-option-explained","title":"Fremanezumab for Chronic Migraine: A New Preventive Treatment Option Explained","description":"\u003cp\u003e\u003cstrong\u003eMain finding:\u003c\/strong\u003e In a large Phase 3 clinical trial involving 1,130 patients with chronic migraine, treatment with fremanezumab (a new type of injectable medication) significantly reduced the number of headache days per month compared to a placebo (inactive injection). Over a 12-week period, patients receiving monthly fremanezumab injections experienced an average reduction of 4.6 headache days per month, while patients receiving placebo experienced a reduction of only 2.5 days — a difference that was highly statistically significant (P\u0026lt;0.001). The medication was generally well-tolerated, though injection-site reactions such as pain and redness were common.\u003c\/p\u003e\n\n\u003ch1\u003eFremanezumab for Chronic Migraine: A New Preventive Treatment Option Explained\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Chronic Migraine: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#fremanezumab\"\u003eFremanezumab: A New Approach to Preventing Migraine\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#participants\"\u003eWho Participated in the Trial\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: Did Fremanezumab Work?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What the Trial Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFremanezumab reduced chronic migraine headache days by 4.3–4.6 per month versus 2.5 with placebo in a 12-week trial of 1,130 patients.\u003c\/li\u003e\n\u003cli\u003e38%–41% of fremanezumab patients achieved at least a 50% reduction in headache days, compared to 18% on placebo.\u003c\/li\u003e\n\u003cli\u003eFremanezumab worked within 4 weeks and also reduced acute headache medication use by 3.7–4.2 days per month.\u003c\/li\u003e\n\u003cli\u003eInjection-site reactions occurred in 47% of treated patients; most side effects were mild to moderate.\u003c\/li\u003e\n\u003cli\u003eThis study lasted only 12 weeks, so long-term safety, effectiveness, and rare side effects require further research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Chronic Migraine: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eMigraine is far more than just a bad headache. It is a complex neurological disorder characterized by recurrent attacks of throbbing or pulsating head pain that is at least moderate in severity. According to the background information in this study, migraine affects an estimated 15 to 18% of the global population, making it one of the most common neurological conditions in the world. It is also a leading cause of disability worldwide, meaning it prevents millions of people from working, attending school, and participating in daily life.\u003c\/p\u003e\n\n\u003cp\u003eChronic migraine is a particularly severe form of the condition. It occurs in approximately 2% of the population and is defined as experiencing at least 15 headache days per month for a period of at least 3 months. For people living with chronic migraine, the pain comes almost daily or near-daily, leading to significant functional impairment and a substantially lower quality of life compared to those with less frequent migraines.\u003c\/p\u003e\n\n\u003cp\u003eMedical experts have long agreed that patients with chronic migraine should receive preventive treatment — therapy designed to reduce the frequency and severity of migraine attacks before they start. However, the study authors note that existing preventive treatments are often underused, poorly adhered to, associated with troublesome side effects, or simply ineffective for many patients. This gap in effective treatment options is exactly why researchers have been searching for new approaches.\u003c\/p\u003e\n\n\u003ch2 id=\"fremanezumab\"\u003eFremanezumab: A New Approach to Preventing Migraine\u003c\/h2\u003e\n\n\u003cp\u003eFremanezumab (also known by its research name TEV-48125) represents a fundamentally new class of migraine treatment. It is a humanized monoclonal antibody — a laboratory-designed protein that acts like a guided missile to target a specific substance in the body. In this case, fremanezumab targets and neutralizes a molecule called \u003cstrong\u003ecalcitonin gene-related peptide (CGRP)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eCGRP is a 37-amino acid neuropeptide (a small protein fragment) that plays a central role in the chain of events that triggers migraines. During a migraine attack, CGRP levels rise, causing blood vessels to dilate (widen) and inflammation to develop in the brain's protective membranes. Fremanezumab works by binding to both the alpha (α) and beta (β) forms of CGRP, essentially \"mopping up\" this pain-promoting molecule before it can trigger the migraine cascade.\u003c\/p\u003e\n\n\u003cp\u003eUnlike some other treatments, fremanezumab targets the CGRP \u003cem\u003eligand\u003c\/em\u003e itself, not the receptor. It offers flexible dosing and is administered as a subcutaneous (under-the-skin) injection, similar to how insulin is given for diabetes. Preceding this Phase 3 trial, a Phase 2 study in patients with chronic migraine had shown significant reductions in both migraine days and headache days compared to placebo, with no serious treatment-related side effects. Those promising results paved the way for this larger, more definitive investigation.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis was a randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial — the gold standard design for testing whether a new medication truly works. \"Randomized\" means patients were assigned to treatment groups by chance; \"double-blind\" means that neither the patients nor the doctors and researchers knew who was receiving the real medication and who was receiving placebo, eliminating bias; and \"placebo-controlled\" means one group received an inactive injection for comparison.\u003c\/p\u003e\n\n\u003cp\u003eThe trial was conducted at \u003cstrong\u003e132 headache clinics across nine countries\u003c\/strong\u003e, with patient recruitment taking place from March 2016 through January 2017. It was funded by Teva Pharmaceuticals, the manufacturer of fremanezumab, and was registered on ClinicalTrials.gov under the number NCT02621931. A strict ethical framework was followed, including compliance with the International Conference on Harmonisation Guidelines for Good Clinical Practice, the principles of the Declaration of Helsinki, and all relevant national and local regulations. All participants signed informed consent documents.\u003c\/p\u003e\n\n\u003cp\u003eThe trial design consisted of three phases: a screening visit, a 28-day preintervention (baseline observation) period, and a 12-week active intervention period, with a final evaluation at the end of week 12. During the 28-day baseline period, patients recorded detailed information about their headaches in a daily electronic diary using a device called the ERT DIARYpro platform on a Bluebird Pidion BM-170 handheld device. This diary captured data on headache occurrence, duration, pain severity, the presence of symptoms like nausea, vomiting, photophobia (light sensitivity), phonophobia (sound sensitivity), and any medications used.\u003c\/p\u003e\n\n\u003ch3\u003eDosing Regimens: Three Groups, Two Approaches\u003c\/h3\u003e\n\n\u003cp\u003ePatients were randomly assigned in a 1:1:1 ratio to one of three groups:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFremanezumab Quarterly (every 3 months):\u003c\/strong\u003e A single dose of 675 mg (given as three 225 mg\/1.5 ml injections) at the start of the trial, followed by placebo injections at weeks 4 and 8.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFremanezumab Monthly:\u003c\/strong\u003e A 675 mg dose at baseline (also three 225 mg injections), followed by 225 mg injections at weeks 4 and 8.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlacebo:\u003c\/strong\u003e Inactive injections given at baseline, week 4, and week 8.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eAll patients received three abdominal subcutaneous injections at baseline and one injection at weeks 4 and 8, so the experience of receiving the injections was identical across all groups. Randomization was performed electronically and was stratified according to sex, country, and whether the patient was already using a preventive migraine medication. Up to 30% of patients were allowed to continue taking a stable dose of one existing migraine-preventive medication (such as topiramate or a beta-blocker) if it had been started at least 2 months before the trial began.\u003c\/p\u003e\n\n\u003ch3\u003eKey Eligibility Criteria\u003c\/h3\u003e\n\n\u003cp\u003eTo participate, patients had to be between the ages of 18 and 70 years, have a history of migraine (diagnosed according to the International Classification of Headache Disorders, 3rd edition beta version, or ICHD-3 beta) for at least 12 months, and meet the criteria for chronic migraine during the 28-day baseline period — defined as headache of any duration or severity on at least 15 days per month and migraine on at least 8 days per month.\u003c\/p\u003e\n\n\u003cp\u003eKey exclusion criteria included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eUse of onabotulinumtoxinA (Botox) for migraine during the 4 months before screening\u003c\/li\u003e\n  \u003cli\u003eUse of migraine interventions or devices (such as nerve blocks or transcranial magnetic stimulation) during the 2 months before screening\u003c\/li\u003e\n  \u003cli\u003eUse of opioid or barbiturate medications on more than 4 days during the preintervention period\u003c\/li\u003e\n  \u003cli\u003eA documented lack of response to adequate trials of at least two of four categories of preventive medications\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eHow Effectiveness Was Measured\u003c\/h3\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eprimary endpoint\u003c\/strong\u003e of the trial was the mean change from baseline in the average number of headache days per month over the 12-week period after the first dose. A \"headache day\" was carefully defined as a calendar day in which:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eHeadache pain lasted at least 4 consecutive hours and had a peak severity of at least moderate level, \u003cstrong\u003eor\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe patient used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSecondary endpoints included changes in the number of migraine days per month, the percentage of patients achieving at least a 50% reduction in headache days, changes in the use of acute headache medications, and changes in the six-item Headache Impact Test (HIT-6) — a validated questionnaire measuring headache-related disability, with scores ranging from 36 to 78 (higher scores indicating greater disability).\u003c\/p\u003e\n\n\u003cp\u003eStatistical analyses were conducted on a \"modified intention-to-treat\" population, meaning all randomly assigned patients who received at least one dose and had at least 10 days of post-baseline efficacy data. The researchers planned to enroll 1,020 participants to provide 90% statistical power to detect a difference of 1.7±6.3 headache days per month between groups, assuming a 15% discontinuation rate.\u003c\/p\u003e\n\n\u003ch2 id=\"participants\"\u003eWho Participated in the Trial\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e1,130 patients\u003c\/strong\u003e were enrolled and randomly assigned to the three groups: 376 to the fremanezumab quarterly group, 379 to the fremanezumab monthly group, and 375 to the placebo group. The baseline characteristics of the patients were highly similar across all three groups, confirming that randomization worked well.\u003c\/p\u003e\n\n\u003cp\u003eKey baseline characteristics of the participants included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge:\u003c\/strong\u003e Average age was approximately 41 years (42.0±12.4 quarterly, 40.6±12.0 monthly, 41.4±12.0 placebo)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSex:\u003c\/strong\u003e The majority were women — 88% (331 patients) in the quarterly group, 87% (330) in the monthly group, and 88% (330) in the placebo group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBody-mass index:\u003c\/strong\u003e Approximately 26.5 in all groups\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDisease duration:\u003c\/strong\u003e On average, patients had been living with migraine for about 20 years (19.7±12.8, 20.1±12.0, 19.9±12.9 years respectively)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCurrent medication use:\u003c\/strong\u003e About 20-22% were using a preventive medication, and 95% were using acute headache medications as needed\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevious treatments:\u003c\/strong\u003e 28-31% had previously used topiramate; 13-18% had previously used onabotulinumtoxinA\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeadache days:\u003c\/strong\u003e The mean number of headache days (as defined in the trial) per month during baseline was 13.2 in the quarterly group, 12.8 in the monthly group, and 13.3 in the placebo group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMigraine days:\u003c\/strong\u003e Patients experienced an average of 16.2, 16.0, and 16.4 migraine days per month, respectively\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall headache burden:\u003c\/strong\u003e Days with headache of any severity and duration averaged about 20 days per month (20.4, 20.3, and 20.3 days, respectively)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAcute medication use:\u003c\/strong\u003e Patients used acute headache medications on approximately 13 days per month and migraine-specific acute medications on approximately 11 days per month\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDisability score:\u003c\/strong\u003e Baseline HIT-6 scores were elevated in all groups (64.3, 64.6, and 64.1), indicating a severe impact on daily life\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOf the 1,130 patients randomly assigned, \u003cstrong\u003e1,034 patients (92%) completed the trial\u003c\/strong\u003e: 349 (93%) in the quarterly group, 343 (91%) in the monthly group, and 342 (91%) in the placebo group. This high completion rate strengthens confidence in the results.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: Did Fremanezumab Work?\u003c\/h2\u003e\n\n\u003ch3\u003ePrimary Endpoint: Reduction in Headache Days\u003c\/h3\u003e\n\n\u003cp\u003eThe trial met its primary endpoint with clear results. After 12 weeks of treatment, the \u003cstrong\u003eleast-squares mean reduction\u003c\/strong\u003e (the average change, statistically adjusted for factors like sex, country, and baseline preventive medication use) in monthly headache days was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFremanezumab quarterly:\u003c\/strong\u003e -4.3±0.3 days per month\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFremanezumab monthly:\u003c\/strong\u003e -4.6±0.3 days per month\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlacebo:\u003c\/strong\u003e -2.5±0.3 days per month\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth fremanezumab groups showed significantly greater reductions than placebo, with a difference versus placebo of 1.8 and 2.1 days, respectively. The statistical significance was \u003cstrong\u003eP\u0026lt;0.001\u003c\/strong\u003e for both comparisons, meaning there is less than a 0.1% probability that these results occurred by chance.\u003c\/p\u003e\n\n\u003cp\u003eIn practical terms, during the 12-week treatment period, patients receiving placebo experienced an average of 10.4±6.4 headache days per month, compared to 8.5±6.3 days for those on quarterly fremanezumab and 8.0±6.3 days for those on monthly fremanezumab. This translates to roughly two fewer headache days per month over and above the placebo effect — a meaningful improvement for people living with daily or near-daily pain.\u003c\/p\u003e\n\n\u003ch3\u003eSecondary Endpoints: Consistent Benefits Across the Board\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eReduction in migraine days.\u003c\/strong\u003e The fremanezumab groups achieved greater reductions in monthly migraine days: -4.9±0.4 days for quarterly dosing and -5.0±0.4 days for monthly dosing, compared to -3.2±0.4 days for placebo. Both differences were statistically significant (P\u0026lt;0.001).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e\"50% Responder\" rates.\u003c\/strong\u003e This is a key measure used in migraine research — the proportion of patients whose headache frequency is cut by at least half. The results were striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e38% of patients in the quarterly group (141 out of 375) achieved at least a 50% reduction\u003c\/li\u003e\n  \u003cli\u003e41% of patients in the monthly group (153 out of 375) achieved at least a 50% reduction\u003c\/li\u003e\n  \u003cli\u003eOnly 18% of patients in the placebo group (67 out of 371) achieved this benchmark\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth differences were statistically significant at P\u0026lt;0.001. In other words, patients receiving fremanezumab were more than twice as likely to experience a dramatic improvement in their headache frequency compared to those receiving placebo.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReduced need for acute headache medication.\u003c\/strong\u003e Patients in the fremanezumab groups also reduced their use of rescue medications. The mean reduction in days per month using any acute headache medication was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e-3.7±0.3 days for quarterly fremanezumab\u003c\/li\u003e\n  \u003cli\u003e-4.2±0.3 days for monthly fremanezumab\u003c\/li\u003e\n  \u003cli\u003e-1.9±0.3 days for placebo\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth differences versus placebo were significant at P\u0026lt;0.001. This means patients treated with fremanezumab relied less on pain-relieving medications, which is good news because overuse of acute medications can itself lead to medication-overuse headache.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRapid onset of effect.\u003c\/strong\u003e The benefits appeared quickly. In the first 4 weeks after the initial dose, headache days were reduced by -4.4±0.3 days (quarterly) and -4.5±0.3 days (monthly) compared to -2.1±0.3 days for placebo — again, P\u0026lt;0.001 for both. Patients did not have to wait months to see improvement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBenefits in patients not using other preventives.\u003c\/strong\u003e The researchers also analyzed the subgroup of patients who were not receiving any concomitant preventive migraine medication (79% of the quarterly group, 77% of the monthly group, and 79% of the placebo group). This was important to isolate fremanezumab's pure effect. The reductions in headache days were -4.6±0.3 days (quarterly), -4.8±0.3 days (monthly), and -2.6±0.3 days (placebo), with both active-treatment differences versus placebo reaching P\u0026lt;0.001.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImproved quality of life (HIT-6 scores).\u003c\/strong\u003e Headache-related disability decreased significantly more with active treatment. HIT-6 scores dropped by:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e-6.4±0.5 points with quarterly fremanezumab\u003c\/li\u003e\n  \u003cli\u003e-6.8±0.4 points with monthly fremanezumab\u003c\/li\u003e\n  \u003cli\u003e-4.5±0.5 points with placebo\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth differences were statistically significant at P\u0026lt;0.001. A reduction of 6-7 points on the HIT-6 scale represents a clinically meaningful improvement in how migraines affect daily functioning. Importantly, fremanezumab also reduced headache days during the 12-week period when evaluated at all measurement time points, indicating a sustained benefit over the entire dosing interval.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety and Side Effects\u003c\/h2\u003e\n\n\u003cp\u003eAdverse events were reported in a substantial proportion of patients in all three groups, which is typical for studies involving injectable medications:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e64% of patients receiving placebo experienced at least one adverse event\u003c\/li\u003e\n  \u003cli\u003e70% of patients receiving quarterly fremanezumab (P=0.06 compared to placebo)\u003c\/li\u003e\n  \u003cli\u003e71% of patients receiving monthly fremanezumab (P=0.03 compared to placebo)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNotably, the vast majority of events were mild to moderate in severity — 95 to 96% across all three groups. The difference between the fremanezumab and placebo groups was driven largely by reactions at the injection site, which were the most commonly reported adverse events.\u003c\/p\u003e\n\n\u003ch3\u003eInjection-Site Reactions\u003c\/h3\u003e\n\n\u003cp\u003eInjection-site reactions occurred in:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e40% of patients receiving placebo\u003c\/li\u003e\n  \u003cli\u003e47% of patients receiving quarterly fremanezumab (P=0.08 versus placebo)\u003c\/li\u003e\n  \u003cli\u003e47% of patients receiving monthly fremanezumab (P=0.03 versus placebo)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese reactions included redness (erythema), swelling (induration), bruising (ecchymosis), and pain at the injection site. The severity of these reactions did not differ significantly among the three groups. The most common specific adverse event was \u003cstrong\u003einjection-site pain\u003c\/strong\u003e, which occurred in 30% of the quarterly group, 26% of the monthly group, and 28% of the placebo group.\u003c\/p\u003e\n\n\u003cp\u003eA total of 20 patients discontinued the trial due to adverse events: 1% in the quarterly group, 2% in the monthly group, and 2% in the placebo group. This low and even distribution of discontinuation rates suggests that fremanezumab was generally well tolerated.\u003c\/p\u003e\n\n\u003ch3\u003eLiver Function and Other Safety Monitoring\u003c\/h3\u003e\n\n\u003cp\u003eAbnormalities of hepatic (liver) function occurred in 5 patients in each fremanezumab group (approximately 1%) and in 3 patients in the placebo group (less than 1%). The clinical significance of these laboratory abnormalities was not fully characterized in this 12-week trial.\u003c\/p\u003e\n\n\u003cp\u003eSafety monitoring was comprehensive. The researchers checked vital signs (blood pressure, pulse, body temperature, respiratory rate), performed physical examinations, conducted 12-lead electrocardiography (heart monitoring), and ran clinical laboratory tests including blood chemistry, hematology, coagulation, and urinalysis. They also systematically assessed local injection-site reactions both immediately and 1 hour after each injection, tracked suicidal ideation and behavior using the electronic Columbia-Suicide Severity Rating Scale, and tested blood samples for antibodies against the medication (anti-drug antibodies, which could potentially reduce the drug's effectiveness or cause side effects). Injection-site pain was the most common adverse event across all groups, and overall, the side-effect profile was considered acceptable and consistent with previous studies of this class of medication.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThese findings represent a meaningful advance in the preventive treatment of chronic migraine. For patients who have struggled with daily or near-daily headaches, and who may have failed to obtain relief from existing oral preventive medications, fremanezumab offers a new mechanism of action that directly targets a core molecule in the migraine pathway.\u003c\/p\u003e\n\n\u003cp\u003eThe clinical benefits are substantial. Nearly twice as many patients achieved at least a 50% reduction in headache days with fremanezumab compared to placebo (38-41% versus 18%). This is not just statistically significant — it is a level of improvement that can change a patient's day-to-day life, restoring the ability to work, care for family, and participate in social activities.\u003c\/p\u003e\n\n\u003cp\u003eThe rapid onset of benefit is also important. Patients responded within the first month of treatment, and improvements were maintained throughout the 12-week study period. The fact that benefits occurred even in patients who were not on other preventive medications confirms that fremanezumab works on its own, though it can also be added to an existing regimen.\u003c\/p\u003e\n\n\u003cp\u003eThe reduction in acute medication use (3.7-4.2 fewer days per month) is particularly relevant from a kidney, liver, and brain health perspective. Overuse of acute pain medications can actually worsen the migraine cycle, so breaking this cycle with an effective preventive is valuable.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the convenience of the dosing schedules should not be overlooked. The option of receiving an injection either monthly or quarterly provides flexibility for patients, many of whom struggle with having to remember to take daily oral preventive medications. The quarterly regimen was similarly effective to the monthly regimen, which could be very attractive for convenience.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What the Trial Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to contextualize these findings with the limitations of the trial, which the authors candidly acknowledge.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe trial was only 12 weeks long.\u003c\/strong\u003e This is a relatively short time frame for a chronic condition like migraine. The study could demonstrate that fremanezumab works in the short term, but the \u003cstrong\u003elong-term durability, safety, and tolerability of fremanezumab require further study\u003c\/strong\u003e. Questions remain about whether the benefits continue beyond 3 months, whether patients develop resistance over time, and whether any rare long-term side effects emerge.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eA significant placebo effect was observed.\u003c\/strong\u003e Patients in the placebo group also experienced an average reduction of 2.5 headache days per month. This is not unexpected in pain studies, but it underscores that the true drug-specific effect, while clearly significant, is somewhat smaller than the raw reduction — the difference versus placebo was 1.8 to 2.1 headache days per month.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInjection-site reactions were common.\u003c\/strong\u003e While not severe for most patients, the fact that roughly half of fremanezumab-treated patients experienced injection-site reactions is an important consideration. Patients who are needle-averse may find this challenging.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe trial excluded certain complex patients.\u003c\/strong\u003e Notably, patients who had injected onabotulinumtoxinA in the 4 months before screening, those using opioid or barbiturate medications on more than 4 days during the baseline period, and those who had not responded to two of four preventive medication categories were excluded. Therefore, results may not fully generalize to the most treatment-refractory migraine population or those with significant medication overuse.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIndustry funding.\u003c\/strong\u003e The trial was funded by Teva Pharmaceuticals, the developer of fremanezumab. While the authors vouched for the conduct of the trial and the accuracy and completeness of the data, and the trial was registered on ClinicalTrials.gov, patients should be aware that industry-sponsored trials can have inherent biases in design and reporting. The majority of patients were women (87-88%), which is consistent with the epidemiology of migraine but means results in men are less thoroughly characterized.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical significance of liver function tests.\u003c\/strong\u003e Although hepatic function abnormalities occurred in only about 1% of treated patients, the clinical meaning of these lab findings is not fully explained in this 12-week study, and longer-term surveillance would be necessary to understand whether these represent a meaningful safety signal.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients living with chronic migraine, this research provides important new information to discuss with their healthcare provider. Here is what patients might consider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about CGRP-targeting therapies.\u003c\/strong\u003e Fremanezumab is part of a new class of \"anti-CGRP\" medications that have fundamentally changed migraine prevention. Many of these agents have now been approved by regulatory agencies around the world. Discuss with your neurologist or headache specialist whether this medication class may be appropriate for you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your migraine days.\u003c\/strong\u003e Keeping a headache diary — like the electronic diary used in this trial — can help you and your doctor accurately document your headache frequency, triggers, medication use, and response to treatment. The trial's careful definitions (at least 4 hours of pain, moderate severity, or the use of triptan\/ergot medications) can serve as a useful model for tracking your own migraines.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSet realistic expectations.\u003c\/strong\u003e The average reduction in headache days was about 4.3 to 4.6 days per month with fremanezumab, versus 2.5 days with placebo, and 38-41% of patients achieved a 50% or greater reduction. This means that while many patients benefit substantially, not every patient becomes headache-free — and more than half of patients in the trial did not achieve the 50% benchmark.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss dosing frequency with your doctor.\u003c\/strong\u003e Both monthly (225 mg) and quarterly (675 mg every 3 months) regimens were effective in this trial. If you prefer fewer injections, quarterly dosing may be an appealing option worth discussing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlan for injection-site reactions.\u003c\/strong\u003e About 47% of treated patients experienced injection-site reactions such as pain, redness, or swelling. Ask your provider about techniques to minimize discomfort, such as allowing the syringe to reach room temperature, using ice before injection, or rotating injection sites.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not stop your current medications without guidance.\u003c\/strong\u003e The trial allowed patients to continue a stable dose of existing preventive medications, suggesting fremanezumab can be used as an add-on therapy. Never change your migraine treatment plan without consulting your healthcare provider.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember that long-term data are still accumulating.\u003c\/strong\u003e This study only evaluated 12 weeks of treatment. As longer-term follow-up studies are published, they will provide important additional information about the durability of benefits, safety over years of use, and the proper place of this medication in the treatment algorithm.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is chronic migraine and how is it different from regular migraine?\u003c\/h3\u003e\n\u003cp\u003eChronic migraine is a severe form of migraine affecting about 2% of people. It means having at least 15 headache days per month for at least 3 months, with migraine features on at least 8 of those days. It causes daily or near-daily pain and significant impairment in work, school, and daily life.\u003c\/p\u003e\n\u003ch3\u003eHow well did fremanezumab work for chronic migraine in this trial?\u003c\/h3\u003e\n\u003cp\u003eIn a 12-week study of 1,130 patients, fremanezumab reduced monthly headache days by about 4.3 to 4.6 days, compared to 2.5 days with placebo. About 38% to 41% of treated patients had at least a 50% reduction in headache days, versus 18% with placebo. Benefits appeared within the first month.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects did patients experience with fremanezumab?\u003c\/h3\u003e\n\u003cp\u003eThe most common side effects were injection-site reactions, such as pain, redness, swelling, and bruising. These occurred in about 47% of treated patients, compared to 40% with placebo. Most side effects were mild to moderate. About 1% to 2% of patients stopped treatment due to side effects.\u003c\/p\u003e\n\u003ch3\u003eWho was eligible to participate in this trial?\u003c\/h3\u003e\n\u003cp\u003eParticipants were adults aged 18 to 70 with chronic migraine, defined as at least 15 headache days and 8 migraine days per month. They had migraine for at least 12 months. Exclusion criteria included recent Botox use, opioid overuse, or lack of response to two prior preventive medications.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this study on fremanezumab?\u003c\/h3\u003e\n\u003cp\u003eThe trial lasted only 12 weeks, so long-term safety and durability are not yet known. A significant placebo effect occurred, and the true drug-specific reduction was 1.8 to 2.1 headache days per month. Injection-site reactions were common. The study excluded some complex patients, so results may not apply to everyone.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Fremanezumab for the Preventive Treatment of Chronic Migraine\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Stephen D. Silberstein, M.D., David W. Dodick, M.D., Marcelo E. Bigal, M.D., Ph.D., Paul P. Yeung, M.D., M.P.H., Peter J. Goadsby, M.D., Ph.D., Tricia Blankenbiller, M.A., Melissa Grozinski-Wolff, B.S., Ronghua Yang, Ph.D., Yuju Ma, M.S., and Ernesto Aycardi, M.D.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e The New England Journal of Medicine (N Engl J Med 2017;377:2113-22)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e November 30, 2017\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1056\/NEJMoa1709038\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTrial registration:\u003c\/strong\u003e ClinicalTrials.gov number, NCT02621931\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding source:\u003c\/strong\u003e Teva Pharmaceuticals, which also provided the trial medication and performed the data analysis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstitutional affiliations:\u003c\/strong\u003e Thomas Jefferson University (Jefferson Headache Center), Philadelphia; Teva Pharmaceuticals, Frazer, PA; Mayo Clinic Arizona, Phoenix; and King's College London, London.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research published in a leading medical journal. It has been written to help patients and the general public understand the study's findings without needing a medical degree. The original scientific article contains additional tables, statistical details, and supplementary materials that may be accessed through the New England Journal of Medicine.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47405674365084,"sku":null,"price":0.0,"currency_code":"CHF","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ch\/fr\/products\/fremanezumab-for-chronic-migraine-a-new-preventive-treatment-option-explained","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}